Not recruiting
Plasma cell myeloma
Not recruitingStudy on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
Registered drugNo placebo
Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:CarfilzomibDaratumumab+4
Countries:
Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Carfilzomib



